# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-193967
Filing Date
2026-04-30
Accepted
2026-04-30 07:15:38
Documents
75
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | kymr-20260331.htm iXBRL | 10-Q | 2628551
2 | EX-31.1 | kymr-ex31_1.htm | EX-31.1 | 18222
3 | EX-31.2 | kymr-ex31_2.htm | EX-31.2 | 18094
4 | EX-32.1 | kymr-ex32_1.htm | EX-32.1 | 10501
5 | EX-32.2 | kymr-ex32_2.htm | EX-32.2 | 10376
| Complete submission text file | 0001193125-26-193967.txt |  | 10603326

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | kymr-20260331.xsd | EX-101.SCH | 1457599
79 | EXTRACTED XBRL INSTANCE DOCUMENT | kymr-20260331_htm.xml | XML | 2006661

Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 26920053
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)